Business Description
EZZ Life Science Holdings Ltd
ISIN : AU0000130569
Description
EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 108.67 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-EBITDA | 0.02 | |||||
Interest Coverage | 876.17 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 7.24 | |||||
Beneish M-Score | -1.43 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 60 | |||||
3-Year EBITDA Growth Rate | 74.7 | |||||
3-Year EPS without NRI Growth Rate | 67.6 | |||||
3-Year FCF Growth Rate | 26 | |||||
3-Year Book Growth Rate | 30.8 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 47.5 | |||||
9-Day RSI | 50.25 | |||||
14-Day RSI | 49.02 | |||||
3-1 Month Momentum % | -48.23 | |||||
6-1 Month Momentum % | -79.38 | |||||
12-1 Month Momentum % | -82.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.57 | |||||
Quick Ratio | 5.8 | |||||
Cash Ratio | 2.81 | |||||
Days Inventory | 55.84 | |||||
Days Sales Outstanding | 28.6 | |||||
Days Payable | 85.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 4.17 | |||||
Dividend Payout Ratio | 0.66 | |||||
3-Year Dividend Growth Rate | 100 | |||||
Forward Dividend Yield % | 8.33 | |||||
5-Year Yield-on-Cost % | 4.3 | |||||
3-Year Average Share Buyback Ratio | -3.3 | |||||
Shareholder Yield % | 4.24 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 72.67 | |||||
Operating Margin % | 8.56 | |||||
Net Margin % | 4.71 | |||||
EBITDA Margin % | 10.43 | |||||
FCF Margin % | -4.42 | |||||
OCF Margin % | -4.29 | |||||
ROE % | 10.85 | |||||
ROA % | 9.01 | |||||
ROIC % | 25.89 | |||||
3-Year ROIIC % | 64.87 | |||||
ROC (Joel Greenblatt) % | 66.75 | |||||
ROCE % | 21.97 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 7.87 | |||||
PE Ratio without NRI | 7.87 | |||||
Price-to-Owner-Earnings | 3.34 | |||||
PS Ratio | 0.37 | |||||
PB Ratio | 0.81 | |||||
Price-to-Tangible-Book | 0.81 | |||||
EV-to-EBIT | 1.57 | |||||
EV-to-EBITDA | 1.44 | |||||
EV-to-Revenue | 0.15 | |||||
EV-to-FCF | -4.01 | |||||
Price-to-GF-Value | 0.33 | |||||
Price-to-Graham-Number | 0.53 | |||||
| Price-to-Net-Current-Asset-Value | 0.84 | |||||
| Price-to-Net-Cash | 2.67 | |||||
Earnings Yield (Greenblatt) % | 63.69 | |||||
FCF Yield % | -12.01 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
EZZ Life Science Holdings Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 61.402 | ||
| EPS (TTM) (A$) | 0.061 | ||
| Beta | 1.4791 | ||
| 3-Year Sharpe Ratio | 0.3 | ||
| 3-Year Sortino Ratio | 0.54 | ||
| Volatility % | 83.74 | ||
| 14-Day RSI | 49.02 | ||
| 14-Day ATR (A$) | 0.018259 | ||
| 20-Day SMA (A$) | 0.47675 | ||
| 12-1 Month Momentum % | -82.02 | ||
| 52-Week Range (A$) | 0.355 - 3.38 | ||
| Shares Outstanding (Mil) | 47.04 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
EZZ Life Science Holdings Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
EZZ Life Science Holdings Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| AUD 0.020000 Cash Dividend | 2025-11-24 | 2.40 (-1.23%) | ||
| AUD 0.020000 Cash Dividend | 2025-05-16 | 1.60 (+3.56%) | ||
| AUD 0.020000 Cash Dividend | 2024-11-05 | 3.18 (-14.05%) |
Show
Entries
EZZ Life Science Holdings Ltd Frequently Asked Questions
What is EZZ Life Science Holdings Ltd(ASX:EZZ)'s stock price today?
The current price of ASX:EZZ is A$0.48. The 52 week high of ASX:EZZ is A$3.38 and 52 week low is A$0.36.
When is next earnings date of EZZ Life Science Holdings Ltd(ASX:EZZ)?
The next earnings date of EZZ Life Science Holdings Ltd(ASX:EZZ) is .
Does EZZ Life Science Holdings Ltd(ASX:EZZ) pay dividends? If so, how much?
The Dividend Yield %  of EZZ Life Science Holdings Ltd(ASX:EZZ) is 4.17% (As of Today), Highest Dividend Payout Ratio of EZZ Life Science Holdings Ltd(ASX:EZZ) was 0.66. The lowest was 0.15. And the median was 0.16. The  Forward Dividend Yield % of EZZ Life Science Holdings Ltd(ASX:EZZ) is 8.33%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on EZZ Life Science Holdings Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers